Sun Damaged Skin Clinical Trial
Official title:
Efficacy Evaluation of Products Against Long Wavelength Ultraviolet A1 and Visible Light Induced Biological Effects
Verified date | January 2022 |
Source | Henry Ford Health System |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the efficacy of topical products in providing protection against the visible light and ultraviolet A1 (UVA1) part of sunlight. Ultraviolet radiation and visible light are both components of sunlight that reach the earth. It is important to test these topical products against visible light and UVA1 because our current sunscreens may not protect against these very well.
Status | Active, not recruiting |
Enrollment | 12 |
Est. completion date | June 2022 |
Est. primary completion date | January 18, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient age 18 and older - Patients Fitzpatrick skin phototype (SPT) III-IV with normal skin health - Patient able to understand requirements of the study and risks involved Exclusion Criteria: - A recent history of vitiligo, melasma, and other disorders of pigmentation with the exception of post inflammatory hyperpigmentation - A history of a relevant skin condition on any part of the patient's body (e.g. atopic dermatitis, eczema, vitiligo, sun burn, etc. - A known history of photodermatoses - A known history of photosensitivity disorders - A known history of melanoma or non-melanoma skin cancers |
Country | Name | City | State |
---|---|---|---|
United States | Department of Dermatology, Henry Ford Medical Center, 3031 West Grand Boulevard, | Detroit | Michigan |
Lead Sponsor | Collaborator |
---|---|
Henry Ford Health System | L'Oreal |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Investigator's Global Assessment (IGA) | Assesses erythema and pigmentation | through study completion, an average of 1 week | |
Primary | Change in Colorimetry | Measures erythema and pigmentation | through study completion, an average of 1 week | |
Primary | Change in Diffuse Reflectance Spectroscopy | Measures erythema and pigmentation | through study completion, an average of 1 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05300542 -
Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema
|
N/A | |
Completed |
NCT05865431 -
Singlet Oxygen Quantification After Skin Exposure to Ultraviolet A (UVA) Light
|
N/A | |
Completed |
NCT05926791 -
Photoprotective Effects of a SPF50+ Sunscreen on Skin Genotoxicity Induced by Repeated Chronic Outdoor Sun Exposure
|
||
Completed |
NCT05398237 -
An Assessment of TLR4 and TOPK/PRPK Signaling in Sun Damaged Human Skin Acutely Exposed to Solar Simulated Light
|
N/A | |
Completed |
NCT05162300 -
Same-Day Combination of VI Peel and Botox for Correction of Sun Damage, Fine Lines and Wrinkles
|
Phase 4 | |
Completed |
NCT03110159 -
DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients
|
Phase 1/Phase 2 | |
Completed |
NCT03006185 -
Laser and Microdermabrasion Before Photodynamic Therapy for Actinic Keratoses in Field-cancerized Skin
|
Phase 2 | |
Enrolling by invitation |
NCT03007589 -
Natural Sunlight Protection and Simulated Sunlight Protection Offered by Sunscreens and Fabrics
|
N/A |